Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095282 | 1.00 | ATM (0.34) | ATMCYP19A1SIGMAR1RAB9AAGTR2 | |
| SCHEMBL8786851 | 1.00 | ATM (0.34) | ATMCYP19A1SIGMAR1RAB9AAGTR2 | |
| SCHEMBL9130961 | 0.88 | CYP19A1 (0.42) | CYP19A1SIGMAR1 | |
| SCHEMBL9738223 | 0.88 | CYP19A1 (0.42) | CYP19A1SIGMAR1 | |
| SCHEMBL6399031 | 0.86 | CYP19A1 (0.31) | CYP19A1SIGMAR1 | |
| SCHEMBL8805750 | 0.84 | SIGMAR1 (0.33) | CYP19A1SIGMAR1FAAH | |
| SCHEMBL8805757 | 0.84 | SIGMAR1 (0.33) | CYP19A1SIGMAR1 | |
| SCHEMBL7805577 | 0.82 | ECE1 (0.33) | CYP19A1SIGMAR1 | |
| SCHEMBL9567186 | 0.82 | FAAH (0.32) | CYP19A1FAAH | |
| SCHEMBL9567071 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342005-B2 | Antibiotic compounds | ASTRAZENECA UK LIMITED (GB) | 2008-03-11 | — | — | US | disclosed |
| US-7041836-B2 | Antibiotic compounds | ASTRAZENECA UK LIMITED (GB) | 2006-05-09 | — | — | US | disclosed |
| US-20050209212-A1 | Antibiotic compounds | ASTRAZENECA UK LIMITED | 2005-09-22 | — | — | US | disclosed |
| US-20030144264-A1 | Antibiotic compounds | ZENECA LIMITED | 2003-07-31 | — | — | US | disclosed |
| US-6541491-B1 | Treating ras mediated diseases, especially cancer. | ZENECA LIMITED (GB) | 2003-04-01 | — | — | US | disclosed |
| US-6521612-B2 | Antibiotic against grampositive, gramnegative bacteria | ZENECA LTD. (GB) | 2003-02-18 | — | — | US | disclosed |
| US-20020042408-A1 | Antibiotic compounds | ZENECA LIMITED | 2002-04-11 | — | — | US | disclosed |
| US-6232338-B1 | 4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors | ZENECA LIMITED (GB) | 2001-05-15 | — | — | US | disclosed |
| US-6187804-B1 | Antibiotic compounds | ZENECA LIMITED (GB) | 2001-02-13 | — | — | US | disclosed |
| US-6180622-B1 | ANTIMICROBIAL ACTIVITY AGAINST A WIDE RANGE OF BACTERIA INCLUDING GRAM-POSITIVE BACTERIA, GRAM-NEGATIVE BACTERIA, BETA-LACTAMASE-PRODUCING BACTERIA, RESISTANT PSEUDOMONAS AERUGINOSA,METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS AND | MEIJI SEIKA KAISHA, LTD. (JP) | 2001-01-30 | — | — | US | disclosed |
| US-5527791-A | Carbapenem antibiotic compounds | ZENECA LIMITED (GB) | 1996-06-18 | — | — | US | disclosed |
| US-5478820-A | Carbapenem deivatives; bactericides | ZENECA LTD. (GB) | 1995-12-26 | — | — | US | disclosed |
| US-5441949-A | Carbapenem antibiotic compounds | ZENECA LIMITED (GB) | 1995-08-15 | — | — | US | disclosed |
| EP-0592167-A1 | Antibiotic pyrrolidinylthiopenem derivatives | ZENECA LIMITED (GB) | 1994-04-13 | — | — | EP | disclosed |
| EP-0590885-A1 | Antibiotic carbapenem compounds | ZENECA LIMITED (GB) | 1994-04-06 | — | — | EP | disclosed |
| EP-0581500-A1 | Antibiotic carbapenem compounds | ZENECA LIMITED (GB) | 1994-02-02 | — | — | EP | disclosed |
| EP-0579826-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993015078-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
| WO-1992017481-A1 | ANTIBIOTIC CARBAPENEM DERIVATIVES | ZENECA LTD. (GB) | 1992-10-15 | — | — | WO | disclosed |
| EP-0508682-A1 | Antibiotic carbapenem derivatives | ZENECA LIMITED (GB) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209212-A1 | Antibiotic compounds | NRDC, NPR3, NGLY1 | ATM 3490/4885CYP19A1 2755/4885SIGMAR1 550/4885 |
| US-20020042408-A1 | Antibiotic compounds | NRDC, NGLY1, NR4A1 | ATM 3895/4885CYP19A1 3153/4885SIGMAR1 149/4885 |
| US-20030144264-A1 | Antibiotic compounds | NRDC, NGLY1, NR4A1 | ATM 3950/4885CYP19A1 3391/4885SIGMAR1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.